Lisa Anson, chief executive of Redx Pharma PLC (LON:REDX) says the out-license deal with AstraZeneca for its fibrosis porcupine inhibitor is good news for the company and also for people suffering from the condition. Using a porcupine inhibitor in lung-scarring diseases such as IPF is a novel approach, she says, and Astra will take on the drug through all its development and clinical work from here on. Redx has another fibrosis treatment under development that uses a different methodology, so that means two different ways of coming at what is a very nasty condition, she adds. Astra is paying US$17mln upfront for an exclusive licence with up to US$360mln in milestone payments and single-digit royalty payments on sales also part of the deal.
Redx Pharma PLC in a great place to move forward after Astra deal says CEO
Quick facts: Redx Pharma PLC
Price: 57.5 GBX
Market Cap: £112.27 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...FOR OUR FULL DISCLAIMER CLICK HERE